| Characteristics . | Number of studies (%) . |
|---|---|
| Strategy | |
| MR | 31 (30.4) |
| Multi-omic-based | 15 (14.7) |
| Network-based | 56 (54.9) |
| Sample size | |
| Very large (≥10,000 subjects) | 49 (48.0) |
| Large (1000–9999 subjects) | 1 (1.0) |
| Small (<1000 subjects) | 2 (2.0) |
| NAa | 50 (49.0) |
| Phenotyping | |
| EHR-based | 11 (10.8) |
| Epidemiology based | 91 (89.2) |
| Predictor | |
| Use SNP as a proxy | 38 (37.3) |
| Drug–gene interactionb | 64 (62.7) |
| Replication analysis | |
| Yes | 18 (17.6) |
| Another independent population | 11 (10.8) |
| In vitro or in vivo experiments | 6 (5.9) |
| Other algorithm/software | 1 (1.0) |
| No | 84 (82.4) |
| Characteristics . | Number of studies (%) . |
|---|---|
| Strategy | |
| MR | 31 (30.4) |
| Multi-omic-based | 15 (14.7) |
| Network-based | 56 (54.9) |
| Sample size | |
| Very large (≥10,000 subjects) | 49 (48.0) |
| Large (1000–9999 subjects) | 1 (1.0) |
| Small (<1000 subjects) | 2 (2.0) |
| NAa | 50 (49.0) |
| Phenotyping | |
| EHR-based | 11 (10.8) |
| Epidemiology based | 91 (89.2) |
| Predictor | |
| Use SNP as a proxy | 38 (37.3) |
| Drug–gene interactionb | 64 (62.7) |
| Replication analysis | |
| Yes | 18 (17.6) |
| Another independent population | 11 (10.8) |
| In vitro or in vivo experiments | 6 (5.9) |
| Other algorithm/software | 1 (1.0) |
| No | 84 (82.4) |
MR, Mendelian randomization; EHR, electronic health record.
aThese studies performed drug repurposing by using publicly available multi-class sources regarding human omic data, drug and disease information, not in a specific population.
bStudies in this category first identified susceptibility genes and then referred to drug information from publicly available databases to evaluate the druggability of the identified markers or to explore potential repurposed indications for existing drugs based on the shared similarity.
| Characteristics . | Number of studies (%) . |
|---|---|
| Strategy | |
| MR | 31 (30.4) |
| Multi-omic-based | 15 (14.7) |
| Network-based | 56 (54.9) |
| Sample size | |
| Very large (≥10,000 subjects) | 49 (48.0) |
| Large (1000–9999 subjects) | 1 (1.0) |
| Small (<1000 subjects) | 2 (2.0) |
| NAa | 50 (49.0) |
| Phenotyping | |
| EHR-based | 11 (10.8) |
| Epidemiology based | 91 (89.2) |
| Predictor | |
| Use SNP as a proxy | 38 (37.3) |
| Drug–gene interactionb | 64 (62.7) |
| Replication analysis | |
| Yes | 18 (17.6) |
| Another independent population | 11 (10.8) |
| In vitro or in vivo experiments | 6 (5.9) |
| Other algorithm/software | 1 (1.0) |
| No | 84 (82.4) |
| Characteristics . | Number of studies (%) . |
|---|---|
| Strategy | |
| MR | 31 (30.4) |
| Multi-omic-based | 15 (14.7) |
| Network-based | 56 (54.9) |
| Sample size | |
| Very large (≥10,000 subjects) | 49 (48.0) |
| Large (1000–9999 subjects) | 1 (1.0) |
| Small (<1000 subjects) | 2 (2.0) |
| NAa | 50 (49.0) |
| Phenotyping | |
| EHR-based | 11 (10.8) |
| Epidemiology based | 91 (89.2) |
| Predictor | |
| Use SNP as a proxy | 38 (37.3) |
| Drug–gene interactionb | 64 (62.7) |
| Replication analysis | |
| Yes | 18 (17.6) |
| Another independent population | 11 (10.8) |
| In vitro or in vivo experiments | 6 (5.9) |
| Other algorithm/software | 1 (1.0) |
| No | 84 (82.4) |
MR, Mendelian randomization; EHR, electronic health record.
aThese studies performed drug repurposing by using publicly available multi-class sources regarding human omic data, drug and disease information, not in a specific population.
bStudies in this category first identified susceptibility genes and then referred to drug information from publicly available databases to evaluate the druggability of the identified markers or to explore potential repurposed indications for existing drugs based on the shared similarity.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
